AVITA Medical Past Earnings Performance
Past criteria checks 0/6
AVITA Medical's earnings have been declining at an average annual rate of -5.8%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 30.1% per year.
Key information
-5.8%
Earnings growth rate
0.6%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 30.1% |
Return on equity | -468.8% |
Net Margin | -95.5% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Oct 04AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 11AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Jul 18Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?
Jun 18Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding
Apr 12AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39%
Feb 02The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32%
Oct 20Avita Medical appoints James Corbett as CEO
Sep 29AVITA Medical says trial evaluating its RECELL system to treat vitiligo met main goal
Sep 12Avita's burn therapy Recell gets insurance coverage in Japan following approval
Sep 01AVITA Medical GAAP EPS of -$0.25 beats by $0.15, revenue of $8.34M beats by $1.18M
Aug 11AVITA Medical Is Interesting, But Not Just Yet
Dec 21AVITA Medical reports preliminary Q2 revenue in-line with consensus
Jan 12AVITA: COVID-19's Impact
Nov 17Revenue & Expenses Breakdown
How AVITA Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 60 | -57 | 88 | 22 |
30 Jun 24 | 54 | -50 | 80 | 21 |
31 Mar 24 | 51 | -45 | 72 | 21 |
31 Dec 23 | 50 | -35 | 66 | 21 |
30 Sep 23 | 45 | -34 | 59 | 17 |
30 Jun 23 | 41 | -31 | 53 | 17 |
31 Mar 23 | 37 | -26 | 48 | 15 |
31 Dec 22 | 34 | -27 | 45 | 14 |
30 Sep 22 | 32 | -30 | 44 | 15 |
30 Jun 22 | 30 | -30 | 43 | 14 |
31 Mar 22 | 32 | -29 | 41 | 15 |
31 Dec 21 | 33 | -25 | 38 | 16 |
30 Sep 21 | 31 | -22 | 34 | 15 |
30 Jun 21 | 29 | -27 | 37 | 15 |
31 Mar 21 | 23 | -35 | 42 | 13 |
31 Dec 20 | 18 | -44 | 50 | 11 |
30 Sep 20 | 16 | -49 | 54 | 11 |
30 Jun 20 | 14 | -42 | 49 | 9 |
31 Mar 20 | 12 | -36 | 43 | 8 |
31 Dec 19 | 11 | -28 | 35 | 7 |
30 Sep 19 | 8 | -23 | 29 | 7 |
30 Jun 19 | 5 | -25 | 28 | 8 |
31 Mar 19 | 4 | -22 | 27 | 6 |
31 Dec 18 | 2 | -18 | 17 | 10 |
30 Sep 18 | 1 | -15 | 15 | 10 |
30 Jun 18 | 1 | -13 | 16 | 6 |
31 Mar 18 | 1 | -12 | 12 | 8 |
31 Dec 17 | 1 | -11 | 12 | 7 |
30 Sep 17 | 1 | -10 | 11 | 6 |
30 Jun 17 | 1 | -9 | 11 | 5 |
31 Mar 17 | 1 | -8 | 10 | 4 |
31 Dec 16 | 1 | -7 | 8 | 3 |
30 Sep 16 | 1 | -8 | 9 | 3 |
30 Jun 16 | 1 | -8 | 8 | 3 |
31 Mar 16 | 1 | -8 | 7 | 3 |
31 Dec 15 | 1 | -7 | 5 | 3 |
30 Sep 15 | 1 | -6 | 5 | 3 |
30 Jun 15 | 1 | -6 | 4 | 3 |
31 Mar 15 | 1 | -5 | 4 | 2 |
31 Dec 14 | 1 | -5 | 5 | 2 |
30 Sep 14 | 2 | -5 | 6 | 2 |
30 Jun 14 | 3 | -5 | 7 | 2 |
31 Mar 14 | 3 | -6 | 7 | 2 |
31 Dec 13 | 3 | -7 | 8 | 2 |
Quality Earnings: RCEL is currently unprofitable.
Growing Profit Margin: RCEL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RCEL is unprofitable, and losses have increased over the past 5 years at a rate of 5.8% per year.
Accelerating Growth: Unable to compare RCEL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RCEL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: RCEL has a negative Return on Equity (-468.81%), as it is currently unprofitable.